It is hypothesized that anti-IL-4 and anti-IL-13 therapies could decrease asthma exacerbations by inhibiting eosinophilic and airway inflammation. Reducing asthma exacerbation risk is a key target of disease management. The improvements in asthma-related quality of life with dupilumab treatment may contribute to preventing severe asthma exacerbations, particularly in patients with nasal polyposis.
Vietri, L., D’Alessandro, M., Zuccon., U. (2022). Real-life experience of severe asthma patients on Dupilumab treatment in Pordenone’s Hospital.
Real-life experience of severe asthma patients on Dupilumab treatment in Pordenone’s Hospital.
Lucia Vietri
Writing – Original Draft Preparation
;Miriana d’Alessandro;
2022-01-01
Abstract
It is hypothesized that anti-IL-4 and anti-IL-13 therapies could decrease asthma exacerbations by inhibiting eosinophilic and airway inflammation. Reducing asthma exacerbation risk is a key target of disease management. The improvements in asthma-related quality of life with dupilumab treatment may contribute to preventing severe asthma exacerbations, particularly in patients with nasal polyposis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Poster su real life experience Dupilumab-2022.pdf
accesso aperto
Descrizione: Poster
Tipologia:
PDF editoriale
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
3.38 MB
Formato
Adobe PDF
|
3.38 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/1262674